All In Biotech

Drug Trial Radar · NCT06546735

Efficacy and Safety of Two Fixed-dose Combinations in Men With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia. (BENIPRO)

Randomized, Double-blind, Double-masked, Parallel-group, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Two Fixed-dose Combinations in Men With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia.

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 816 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

816

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Apr 30, 2028

Study completion Aug 30, 2028

Sponsor

Lead sponsor
Eurofarma Laboratorios S.A.Industry
Sponsor type
Industry
First posted
Aug 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The clinical trial to evaluate the fixed-dose combination (N0728), with the aim of providing the Brazilian market with an alternative, potentially effective, safe and convenient therapeutic approach for the treatment of Lower Urinary Tract Symptoms (LUTS) in men with Benign Prostatic Hyperplasia (BPH). The fixed-dose combination has synergistic action between drugs from different classes and offers significant potential advantages, such as better adherence to treatment. The trial will assess the non-inferiority in efficacy and safety of the proposed fixed-dose combination compared to alpha-adrenergic antagonists.

Conditions

  • Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms

Interventions

  • N0728Drug

    1 tablet of the test drug (N0728) and 1 tablet of placebo of Vesomni®.

  • Vesomni®Drug

    1 tablet of the comparator drug Vesomni® and 1 tablet of the placebo of the test drug.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The mean number of urgency episodes per dayTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Eurofarma Laboratorios S.A

    São Paulo, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.